Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+20.7%
5Y CAGR+22.2%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+20.7%/yr
vs +42.7%/yr prior
5Y CAGR
+22.2%/yr
Consistent
Acceleration
-21.9pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.7x
Strong expansion
Streak
9 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $784.19M | +10.9% |
| 2025 | $707.17M | +17.0% |
| 2024 | $604.63M | +35.6% |
| 2023 | $445.74M | +5.7% |
| 2022 | $421.74M | +46.8% |
| 2021 | $287.32M | +58.6% |
| 2020 | $181.15M | +68.3% |
| 2019 | $107.61M | +49.3% |
| 2018 | $72.08M | +5.4% |
| 2017 | $68.40M | - |